Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
Authors
Keywords
-
Journal
Nature Reviews Endocrinology
Volume 12, Issue 10, Pages 566-592
Publisher
Springer Nature
Online
2016-06-26
DOI
10.1038/nrendo.2016.86
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
- (2016) Michael Nauck et al. DIABETES CARE
- Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
- (2016) John P. Bilezikian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment
- (2015) Heidi Storgaard et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future
- (2015) CJ Bailey CLINICAL PHARMACOLOGY & THERAPEUTICS
- Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
- (2015) Feng Sun et al. CLINICAL THERAPEUTICS
- Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus
- (2015) Christopher S. Kovacs et al. CLINICAL THERAPEUTICS
- Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
- (2015) Juris J. Meier et al. DIABETES CARE
- Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment
- (2015) Luc Van Gaal et al. DIABETES CARE
- Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
- (2015) Francesco Giorgino et al. DIABETES CARE
- Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
- (2015) Ngozi Erondu et al. DIABETES CARE
- Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5
- (2015) John B. Buse et al. DIABETES CARE
- Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Giulia Ferrannini et al. DIABETES CARE
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Anne L. Peters et al. DIABETES CARE
- Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
- (2015) Julio Rosenstock et al. DIABETES CARE
- Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension
- (2015) N. B. Amin et al. DIABETES OBESITY & METABOLISM
- Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin
- (2015) N. B. Amin et al. DIABETES OBESITY & METABOLISM
- Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials
- (2015) M. Reaney et al. DIABETES OBESITY & METABOLISM
- Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study
- (2015) R. S. Weinstock et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
- (2015) T. Karagiannis et al. DIABETES OBESITY & METABOLISM
- One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial
- (2015) S. C. L. Gough et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial
- (2015) A. Ahmann et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes
- (2015) G. Fulcher et al. DIABETES OBESITY & METABOLISM
- Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial
- (2015) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials
- (2015) Pavel S. Roshanov et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
- (2015) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes
- (2015) Hans-Ulrich Haering et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Empagliflozin as add-on to metformin in people with Type 2 diabetes
- (2015) L. Merker et al. DIABETIC MEDICINE
- Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial
- (2015) Wolfgang Kothny et al. DIABETOLOGIA
- DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP–glucagon counterregulatory axis in mice
- (2015) Siri Malmgren et al. DIABETOLOGIA
- The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis
- (2015) Emma O. Billington et al. DIABETOLOGIA
- Trelagliptin: First Global Approval
- (2015) Kate McKeage DRUGS
- Omarigliptin: First Global Approval
- (2015) Celeste B. Burness DRUGS
- Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
- (2015) Ele Ferrannini et al. EUROPEAN HEART JOURNAL
- Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review
- (2015) Shashank R Joshi et al. EXPERT OPINION ON PHARMACOTHERAPY
- Efficacy and Safety of Bromocriptine-QR in Type 2 Diabetes: A Systematic Review and Meta-Analysis
- (2015) W. Liang et al. HORMONE AND METABOLIC RESEARCH
- Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study
- (2015) Ann V. Schwartz et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study
- (2015) Yuhao Huang et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
- (2015) Lawrence Blonde et al. LANCET
- Five-Year Efficacy and Safety Data of Exenatide Once Weekly
- (2015) Carol H. Wysham et al. MAYO CLINIC PROCEEDINGS
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- (2015) Caroline Bonner et al. NATURE MEDICINE
- Islet α cells and glucagon—critical regulators of energy homeostasis
- (2015) Jonathan E. Campbell et al. Nature Reviews Endocrinology
- Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Rodney A. Hayward et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients
- (2015) K. Esposito et al. BMJ Open
- Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study
- (2015) Nobuya Inagaki et al. Lancet Diabetes & Endocrinology
- Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study
- (2015) Szu-Chun Hung et al. Lancet Diabetes & Endocrinology
- Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study
- (2015) Hiroaki Ueno et al. Diabetes Therapy
- Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study
- (2015) Hiroaki Ueno et al. Diabetes Therapy
- Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
- (2015) Sri Harsha Tella et al. Therapeutic Advances in Endocrinology and Metabolism
- The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis
- (2015) Jessica E. Potts et al. PLoS One
- Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis
- (2015) Elizabeth S. Mearns et al. PLoS One
- Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial
- (2014) Rury R. Holman et al. AMERICAN HEART JOURNAL
- Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus
- (2014) André J. Scheen CLINICAL PHARMACOKINETICS
- Safety of Metformin in Patients with Chronic Obstructive Pulmonary Disease and Type 2 Diabetes Mellitus
- (2014) Andrew W. Hitchings et al. COPD-Journal of Chronic Obstructive Pulmonary Disease
- Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies
- (2014) Paul Nyirjesy et al. CURRENT MEDICAL RESEARCH AND OPINION
- Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study
- (2014) Tanja Dujic et al. DIABETES
- Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?
- (2014) Philip Home et al. DIABETES CARE
- Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro
- (2014) Julio Rosenstock et al. DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)
- (2014) John B. Buse et al. DIABETES CARE
- The Pharmacogenetics of Type 2 Diabetes: A Systematic Review
- (2014) Nisa M. Maruthur et al. DIABETES CARE
- Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study
- (2014) Lawrence A. Leiter et al. DIABETES CARE
- Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes
- (2014) Bruce Neal et al. DIABETES CARE
- HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin
- (2014) Bo Ahrén et al. DIABETES CARE
- Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
- (2014) Hans-Ulrich Häring et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)
- (2014) Guillermo Umpierrez et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
- (2014) Carol Wysham et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
- (2014) Michael Nauck et al. DIABETES CARE
- Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
- (2014) Julio Rosenstock et al. DIABETES CARE
- Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
- (2014) Ilkka Tikkanen et al. DIABETES CARE
- Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1 324 515 patients from observational studies
- (2014) T. Wang et al. DIABETES OBESITY & METABOLISM
- Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin
- (2014) M. A. Nauck et al. DIABETES OBESITY & METABOLISM
- A systematic review and meta-analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes
- (2014) L. J. Schmidt et al. DIABETES OBESITY & METABOLISM
- Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5
- (2014) P. D. Home et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled
- (2014) J. Reusch et al. DIABETES OBESITY & METABOLISM
- Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin
- (2014) S. Grandy et al. DIABETES OBESITY & METABOLISM
- Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials
- (2014) B. Ahrén et al. DIABETES OBESITY & METABOLISM
- Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5)
- (2014) Z. Skrivanek et al. DIABETES OBESITY & METABOLISM
- Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis
- (2014) Y. G. Kim et al. DIABETES OBESITY & METABOLISM
- Novel therapeutics for type 2 diabetes: insulin resistance
- (2014) Q.-A. Altaf et al. DIABETES OBESITY & METABOLISM
- Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus
- (2014) S. Sha et al. DIABETES OBESITY & METABOLISM
- Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia)
- (2014) Chang Yu Pan et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes
- (2014) Denis Raccah et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub-study of the DREAM trial
- (2014) Z. Punthakee et al. DIABETIC MEDICINE
- Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin
- (2014) Heike Zimdahl et al. DIABETOLOGIA
- HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea
- (2014) Peter N. Weissman et al. DIABETOLOGIA
- Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events
- (2014) Agata Ptaszynska et al. DRUG SAFETY
- Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- (2014) André J. Scheen DRUGS
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis
- (2014) Xu-Ping Yang et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Empagliflozin for the treatment of type 2 diabetes
- (2014) Vidhya Jahagirdar et al. EXPERT OPINION ON PHARMACOTHERAPY
- Efficacy and Safety of Colesevelam in Combination with Pioglitazone in Patients with Type 2 Diabetes Mellitus
- (2014) J. Rosenstock et al. HORMONE AND METABOLIC RESEARCH
- Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus
- (2014) Keith C. Ferdinand et al. HYPERTENSION
- A Randomized Controlled Trial of the Effects of Pioglitazone Treatment on Sympathetic Nervous System Activity and Cardiovascular Function in Obese Subjects With Metabolic Syndrome
- (2014) Nora E. Straznicky et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis
- (2014) Bernard Charbonnel et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)
- (2014) Julio Rosenstock et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes
- (2014) Tesfaye Biftu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
- (2014) Kathleen M Dungan et al. LANCET
- Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis
- (2014) Conrad Eng et al. LANCET
- Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial
- (2014) Peter Stein et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
- (2014) Anila K. Madiraju et al. NATURE
- Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
- (2014) Amy G. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Target of Metformin in Type 2 Diabetes
- (2014) Ele Ferrannini NEW ENGLAND JOURNAL OF MEDICINE
- Metformin in Chronic Kidney Disease: Time for a Rethink
- (2014) J. Heaf PERITONEAL DIALYSIS INTERNATIONAL
- Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics
- (2014) Bennett C Meier et al. Epigenomics
- The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials
- (2014) Yu-nan Sun et al. BMJ Open
- Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials
- (2014) K. Esposito et al. BMJ Open
- Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies
- (2014) L. Li et al. BMJ-British Medical Journal
- Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
- (2014) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial
- (2014) Michaela Diamant et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes
- (2014) Stephen C L Gough et al. Lancet Diabetes & Endocrinology
- Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
- (2014) Martin Ridderstråle et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
- (2014) Anthony H Barnett et al. Lancet Diabetes & Endocrinology
- Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus
- (2014) Kira B. Harris et al. Therapeutic Advances in Endocrinology and Metabolism
- GLP-1 receptor agonists: a review of head-to-head clinical studies
- (2014) Jennifer M. Trujillo et al. Therapeutic Advances in Endocrinology and Metabolism
- Results of a reevaluation of cardiovascular outcomes in the RECORD trial
- (2013) Kenneth W. Mahaffey et al. AMERICAN HEART JOURNAL
- Effect of GLP-1 Mimetics on Blood Pressure and Relationship to Weight Loss and Glycemia Lowering: Results of a Systematic Meta-Analysis and Meta-Regression
- (2013) M. Katout et al. AMERICAN JOURNAL OF HYPERTENSION
- Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial
- (2013) Juan C. Arjona Ferreira et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes
- (2013) John B. Buse et al. ANNALS OF INTERNAL MEDICINE
- State of the art paper The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus
- (2013) Rodolfo Guardado-Mendoza et al. Archives of Medical Science
- Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure
- (2013) Dean T. Eurich et al. Circulation-Heart Failure
- Reponse to Comments on: Butler et al. Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors. Diabetes 2013;62:2595-2604
- (2013) A. E. Butler et al. DIABETES
- Metformin revisited: A critical review of the benefit–risk balance in at-risk patients with type 2 diabetes
- (2013) A.J. Scheen et al. DIABETES & METABOLISM
- Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus
- (2013) D.R. Owens et al. DIABETES & METABOLISM
- Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
- (2013) J. Rosenstock et al. DIABETES CARE
- Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
- (2013) Robert R. Henry et al. DIABETES CARE
- Interpreting Adverse Signals in Diabetes Drug Development Programs
- (2013) C. J. Bailey DIABETES CARE
- Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
- (2013) Bo Ahrén et al. DIABETES CARE
- Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
- (2013) H.-U. Haring et al. DIABETES CARE
- Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin
- (2013) Matthew C. Riddle et al. DIABETES CARE
- Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine
- (2013) Matthew C. Riddle et al. DIABETES CARE
- Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)
- (2013) M. Pinget et al. DIABETES OBESITY & METABOLISM
- Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study
- (2013) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
- (2013) T. Heise et al. DIABETES OBESITY & METABOLISM
- Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
- (2013) C. S. Kovacs et al. DIABETES OBESITY & METABOLISM
- A Randomized, Double-Blind, Comparative Therapy Evaluating Sitagliptin Versus Glibenclamide in Type 2 Diabetes Patients Already Treated with Pioglitazone and Metformin: A 3-Year Study
- (2013) Giuseppe Derosa et al. Diabetes Technology & Therapeutics
- Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials
- (2013) Yifei Zhang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)
- (2013) G. B. Bolli et al. DIABETIC MEDICINE
- Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis
- (2013) Y. G. Kim et al. DIABETOLOGIA
- Efficacy of Anthiyperglycemic Therapies and the Influence of Baseline Hemoglobin A1C: A Meta-Analysis of the Liraglutide Development Program
- (2013) Robert Henry et al. Endocrine Practice
- Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
- (2013) André J Scheen Expert Opinion on Drug Metabolism & Toxicology
- Cardiovascular effects of gliptins
- (2013) André J. Scheen Nature Reviews Cardiology
- Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties
- (2013) P. Arnouts et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT inhibitors in management of diabetes
- (2013) Abd A Tahrani et al. Lancet Diabetes & Endocrinology
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2013) Michael Roden et al. Lancet Diabetes & Endocrinology
- Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial
- (2013) Wenying Yang et al. Lancet Diabetes & Endocrinology
- Drug-Drug Interactions with Glucagon-Like Peptide-1 Receptor Agonists
- (2012) Kathryn M Hurren et al. ANNALS OF PHARMACOTHERAPY
- Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis
- (2012) Haesuk Park et al. ANNALS OF PHARMACOTHERAPY
- Metformin affects the circadian clock and metabolic rhythms in a tissue-specific manner
- (2012) Maayan Barnea et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Mechanisms for Insulin Resistance: Common Threads and Missing Links
- (2012) Varman T. Samuel et al. CELL
- Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
- (2012) Vanita R. Aroda et al. CLINICAL THERAPEUTICS
- Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes
- (2012) J. Rosenstock et al. DIABETES CARE
- Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
- (2012) M. Davies et al. DIABETES CARE
- Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
- (2012) J. C. Arjona Ferreira et al. DIABETES CARE
- Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
- (2012) V. A. Fonseca et al. DIABETES CARE
- Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis
- (2012) C. F. Deacon et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
- (2012) Ö. Ljunggren et al. DIABETES OBESITY & METABOLISM
- Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
- (2012) Y. Seino et al. DIABETES OBESITY & METABOLISM
- Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin
- (2012) D. Devineni et al. DIABETES OBESITY & METABOLISM
- Cardiovascular Biology of the Incretin System
- (2012) John R. Ussher et al. ENDOCRINE REVIEWS
- A randomized placebo controlled double blind crossover study of pioglitazone on left ventricular diastolic function in type 2 diabetes
- (2012) Alun David Hughes et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Vildagliptin Reduces Glucagon during Hyperglycemia and Sustains Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes
- (2012) Johan Farngren et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
- (2012) Baptist Gallwitz et al. LANCET
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Cellular and molecular mechanisms of metformin: an overview
- (2011) Benoit Viollet et al. CLINICAL SCIENCE
- Antidiabetic Agents in Patients with Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: Metabolism and Clinical Practice
- (2011) Masanori Abe et al. CURRENT DRUG METABOLISM
- Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study
- (2011) D. Russell-Jones et al. DIABETES CARE
- Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial
- (2011) M. A. Nauck et al. DIABETES CARE
- Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta-analysis of clinical trials
- (2011) Y. Wang et al. DIABETES OBESITY & METABOLISM
- A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes
- (2011) P. Barrington et al. DIABETES OBESITY & METABOLISM
- Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
- (2011) R. Grempler et al. DIABETES OBESITY & METABOLISM
- Mechanisms Underlying Metformin-Induced Secretion of Glucagon-Like Peptide-1 from the Intestinal L Cell
- (2011) Andrew J. Mulherin et al. ENDOCRINOLOGY
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
- (2011) Jacob Lønborg et al. EUROPEAN HEART JOURNAL
- Pramlintide and the treatment of diabetes: a review of the data since its introduction
- (2011) Lisa M Younk et al. EXPERT OPINION ON PHARMACOTHERAPY
- A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: An analysis of the PROactive study
- (2011) Roman Pfister et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
- (2011) Thomas Blevins et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Management of type 2 diabetes: new and future developments in treatment
- (2011) Abd A Tahrani et al. LANCET
- Biology of Human Sodium Glucose Transporters
- (2011) Ernest M. Wright et al. PHYSIOLOGICAL REVIEWS
- Renal glucose reabsorption inhibitors to treat diabetes
- (2011) Clifford J. Bailey TRENDS IN PHARMACOLOGICAL SCIENCES
- Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
- (2010) Anne Gill et al. Cardiovascular Diabetology
- Dipeptidylpeptitase-4 Inhibitors (Gliptins)
- (2010) André J. Scheen CLINICAL PHARMACOKINETICS
- Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?
- (2010) Mikkel Christensen et al. Current Diabetes Reports
- Hypothalamic AMP-Activated Protein Kinase Regulates Glucose Production
- (2010) C. S. Yang et al. DIABETES
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial
- (2010) E. Ferrannini et al. DIABETES CARE
- Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes
- (2010) J. M. Gaziano et al. DIABETES CARE
- DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
- (2010) J. B. Buse et al. DIABETES CARE
- Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
- (2010) D. R. Matthews et al. DIABETES OBESITY & METABOLISM
- Bromocriptine: old drug, new formulation and new indication
- (2010) R. I. G. Holt et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
- (2010) C. F. Deacon DIABETES OBESITY & METABOLISM
- Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
- (2010) A. Garber et al. DIABETES OBESITY & METABOLISM
- Effect of Repaglinide Versus Glyburide on Postprandial Glucose and Insulin Values in Elderly Patients with Type 2 Diabetes
- (2010) Graydon S. Meneilly Diabetes Technology & Therapeutics
- Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus
- (2010) André J. Scheen et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study
- (2010) C. Filozof et al. DIABETIC MEDICINE
- Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
- (2010) R. E. Ratner et al. DIABETIC MEDICINE
- Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia
- (2010) A. Bellomo Damato et al. DIABETIC MEDICINE
- Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice
- (2010) A. Maida et al. DIABETOLOGIA
- New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser
- (2010) Y. M. Cho et al. DIABETOLOGIA
- Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
- (2010) M. A. Nauck et al. DIABETOLOGIA
- Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
- (2010) T. Seck et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
- (2010) Michaela Diamant et al. LANCET
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Disruption of the clock components CLOCK and BMAL1 leads to hypoinsulinaemia and diabetes
- (2010) Biliana Marcheva et al. NATURE
- Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Drug evaluation: Vildagliptin-metformin single-tablet combination
- (2009) Abd A. Tahrani et al. ADVANCES IN THERAPY
- Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
- (2009) Abd A. Tahrani et al. ADVANCES IN THERAPY
- Glucose transporters in the 21st Century
- (2009) Bernard Thorens et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
- (2009) B. Zinman et al. DIABETES CARE
- Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing
- (2009) J. Rosenstock et al. DIABETES CARE
- Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence
- (2009) Vivian A. Fonseca et al. DIABETES OBESITY & METABOLISM
- Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
- (2009) M. Marre et al. DIABETIC MEDICINE
- Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene
- (2009) H. Mulder et al. DIABETOLOGIA
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
- (2009) D. Russell-Jones et al. DIABETOLOGIA
- In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans
- (2009) M. Obermeier et al. DRUG METABOLISM AND DISPOSITION
- Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-naïve Patients with Type 2 Diabetes
- (2009) J. E. Foley et al. HORMONE AND METABOLIC RESEARCH
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Glycaemic control in type 2 diabetes: Targets and new therapies
- (2009) Abd A. Tahrani et al. PHARMACOLOGY & THERAPEUTICS
- CNS Regulation of Glucose Homeostasis
- (2009) Carol K. L. Lam et al. PHYSIOLOGY
- DPP-4 Inhibitors in Clinical Practice
- (2009) Anna I. Palalau et al. POSTGRADUATE MEDICINE
- Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
- (2008) Y. K. Loke et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- New treatments in type 2 diabetes: a focus on the incretin-based therapies
- (2008) Anthony H. Barnett CLINICAL ENDOCRINOLOGY
- Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
- (2008) David C. Klonoff et al. CURRENT MEDICAL RESEARCH AND OPINION
- Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes
- (2008) J.-F. Gautier et al. DIABETES & METABOLISM
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
- (2008) M. Nauck et al. DIABETES CARE
- Treatment intensification in patients with type 2 diabetes
- (2008) Anthony H. Barnett DIABETES OBESITY & METABOLISM
- Metformin and the intestine
- (2008) C. J. Bailey et al. DIABETOLOGIA
- Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
- (2008) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes
- (2008) Jessica E. Matthews et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
- (2008) Wei Meng et al. JOURNAL OF MEDICINAL CHEMISTRY
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
- Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
- (2008) Alan Garber et al. LANCET
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
- (2008) William Duckworth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-nave elderly patients with type 2 diabetes
- (2007) S. L. Schwarz et al. DIABETES OBESITY & METABOLISM
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started